Nurix Therapeutics Inc
NRIXHealthcare|Biotechnology|USA
$23.08
-1.63 (-6.60%)
Tangible Book
$3.88
About
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Stock Price
+82.2%(1Y)
Pipeline Summary
10 total trials8
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
Recruiting: 5NOT_YET_RECRUITING: 2Completed: 2Terminated: 1
Active Trials (5)
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
NCT04830137Chronic Lymphocytic Leukemia (CLL)
Phase 1Recruiting
Enrollment: 248 participants
Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
NCT06717269Healthy Volunteer
Phase 1Recruiting
Enrollment: 18 participants
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial
Phase 1Recruiting
Enrollment: 345 participants
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL)
Phase 1Recruiting
Enrollment: 572 participants
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500Chronic Lymphocytic Leukemia (CLL)
Phase 2Recruiting
Enrollment: 100 participants
BioScore
4.4/10
Cautious
Ownership
Recent Insider Trades
Ring ChristineSELL
2026-07-0211,008 shares @ $23.56
Hansen GwennSELL
2026-06-255,394 shares @ $20
Ring ChristineSELL
2026-06-2528,935 shares @ $20.06
Ring ChristineSELL
2026-06-028,148 shares @ $16.6
van Houte HansSELL
2026-05-0514,055 shares @ $16.6
Recent News
2026-07-10 16:30:32
2026-07-10 14:05:10
2026-07-10 14:02:45
2026-07-10 12:34:33
2026-07-10 12:30:35
Data last updated: Jul 12, 2026, 07:41 PM